Insights in non-alcoholic fatty liver disease pathophysiology with lipidomic analyses

Annals of Hepatology

Volumn 14, Issue 4, 2015, Pages 567-569

  Almeda Valdes, Paloma ^a   Altamirano Barrera, Alejandra ^b   Méndez Sánchez, Nahum ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b LIVER RESEARCH UNIT   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCEROPHOSPHOLIPID; LIPIDOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SPHINGOMYELIN PHOSPHODIESTERASE; TRIACYLGLYCEROL; CERAMIDE;

ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FATTY LIVER; HUMAN; INTESTINE FLORA; LIPID METABOLISM; LIPID STORAGE; LIPIDOMICS; LIPOTOXICITY; LIVER CIRRHOSIS; LIVER FIBROSIS; MICROBIOME; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; ADIPOSE TISSUE; BLOOD; FEMALE; MORBID OBESITY; POSTOPERATIVE COMPLICATION;

ADIPOSE TISSUE; CERAMIDES; FEMALE; GLYCEROPHOSPHOLIPIDS; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; POSTOPERATIVE COMPLICATIONS;

EID: 84929582849     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31182-2     Document Type: Article

References (12)

1. Corey KE, Misdraji J, Gelrud L, Zheng H, Chung RT, Krauss RM.Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis 2014; 13: 100.
2. Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Mendez-Sanchez N.Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 148-58.
3. Clark JM, Diehl AM.Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-4.
4. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T.Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-39.
5. Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, Wright JK, Matrisian LM, et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS One 2011; 6: e22775.
6. Beyoglu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol 2013; 59: 842-58.
7. Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N, Fernández- Checa JC. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. J Hepatol 2015; 62: 219-33.
8. Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, et al. Circulating phospholipids profiling identifies portal contribution to NASH signature in obesity. J Hepatol 2015; 62: 905-12.
9. Larter CZ, Yeh MM, Haigh WG, Williams J, Brown S, Bell-Anderson KS, Lee SP, et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol 2008; 48: 638-47.
10. Day CP, James OF.Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-5.
11. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006; 3: 321-31.
12. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K.Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19: 338-48.